Evidence map›Paper›PMID 39171392›Full record

ArticleHypertension (Dallas, Tex. : 1979)2024

Collecting Duct Pro(Renin) Receptor Contributes to Unilateral Ureteral Obstruction-Induced Kidney Injury via Activation of the Intrarenal RAS.

Renfei Luo, Kevin T Yang, Fei Wang, Huaqing Zheng, Tianxin Yang

Abstract read
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Biomolecules · 2026
    Article
  3. Renal tubular (pro)renin receptor deletion exacerbates kidney injury inAmerican journal of physiology. Renal physiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Renfei LuoDepartment of Internal Medicine, The University of Utah, Salt Lake City, UT (R.L., K.T.Y., F.W., H.Z., T.Y.).
Kevin T YangDepartment of Internal Medicine, The University of Utah, Salt Lake City, UT (R.L., K.T.Y., F.W., H.Z., T.Y.).
Fei WangDepartment of Internal Medicine, The University of Utah, Salt Lake City, UT (R.L., K.T.Y., F.W., H.Z., T.Y.).ORCID 0000-0001-8405-3561
Huaqing ZhengDepartment of Internal Medicine, The University of Utah, Salt Lake City, UT (R.L., K.T.Y., F.W., H.Z., T.Y.).
Tianxin YangDepartment of Internal Medicine, The University of Utah, Salt Lake City, UT (R.L., K.T.Y., F.W., H.Z., T.Y.).ORCID 0000-0003-4209-2284

Funding

Interaction of PGE2 and intrarenal RAS in AngII-induced hypertensionR01DK104072 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI YANG, TIANXIN · 2015 to 2025
$3.7M
Adipose-derived sPRR controls circadian rhythm of blood pressure through inhibition of renal NCC activityR01HL160020 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI YANG, TIANXIN · 2022 to 2025
$2.4M
Role of (pro)renin receptor in aldosterone signaling in the kidneyR01HL139689 · NHLBI · UNIVERSITY OF UTAH · PI YANG, TIANXIN · 2018 to 2021
$2.3M
Interaction of (pro)renin receptor and PPARy in regulation of plasma volumeR01HL135851 · NHLBI · UNIVERSITY OF UTAH · PI YANG, TIANXIN · 2017 to 2021
$2.3M
The function and regulation of intrarenal aldosterone synthase in ischemia-induced hypertension and renal injuryI01BX004871 · VA · VA SALT LAKE CITY HEALTHCARE SYSTEM · PI Tianxin Yang · 2021 to 2026
–
BLR&D Research Career Scientist Award ApplicationIK6BX005223 · VA · VA SALT LAKE CITY HEALTHCARE SYSTEM · PI YANG, TIANXIN · 2021 to 2025
–
BLRD VA I01 BX004871BLRD VA IK6 BX005223NHLBI NIH HHS R01 HL135851NHLBI NIH HHS R01 HL139689NHLBI NIH HHS R01 HL160020NIDDK NIH HHS R01 DK104072
6 · The paper itself

Abstract

backgroundAlthough the concept of the intrarenal renin-angiotensin system (RAS) in renal disease is well-described in the literature, the precise pathogenic role and mechanism of this local system have not been directly assessed in the absence of confounding influence from the systemic RAS. The present study used novel mouse models of collecting duct (CD)-specific deletion of (pro)renin receptor (PRR) or renin together with pharmacological inhibition of soluble PRR production to unravel the precise contribution of the intrarenal RAS to renal injury induced by unilateral ureteral obstruction.

methodsWe examined the impact of CD-specific deletion of PRR, CD-specific deletion of renin, and S1P (site-1 protease) inhibitor PF429242 treatment on renal fibrosis and inflammation and the indices of the intrarenal RAS in a mouse model of unilateral ureteral obstruction.

resultsAfter 3 days of unilateral ureteral obstruction, the indices of the intrarenal RAS including the renal medullary renin content, activity and mRNA expression, and Ang (angiotensin) II content in obstructed kidneys of floxed mice were all increased. That effect was reversed with CD-specific deletion of PRR, CD-specific deletion of renin, and PF429242 treatment, accompanied by consistent improvement in renal fibrosis and inflammation. On the other hand, renal cortical renin levels were unaffected by unilateral ureteral obstruction, irrespective of the genotype. Similar results were obtained via pharmacological inhibition of S1P, the key protease for the generation of soluble PRR.

conclusionsOur results reveal that PRR-dependent/soluble PRR-dependent activation of CD renin represents a key determinant of the intrarenal RAS and, thus, obstruction-induced renal inflammation and fibrosis.

Indexed as

Kidney Tubules, CollectingReceptors, Cell SurfaceRenin-Angiotensin SystemUreteral ObstructionAnimalsDisease Models, AnimalFibrosisKidneyMaleMiceProrenin ReceptorReninATP6AP2 protein, mouseProrenin ReceptorReceptors, Cell SurfaceReninfibrosisinflammationkidneyprorenin receptorrenin

Identifiers

PMID39171392
PMCPMC11410543

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.